PLAU/uPA (pro form), His, Human

PLAU/uPA (pro form), His, Human

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Z05759
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
PLAU/uPA (pro form) (Ser21-Leu431)_x000D_
Accession # P00749-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized PLAU/uPA (pro form), His, Human at 0.5μg/ml (100μl/Well) on the plate can bind Human uPAR, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 47.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Synonyms PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.